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CObjectives: Inverse probability of treatment weighted Kaplan-Meier
estimates have been developed to compare two treatments in the pres-
ence of confounders in observational studies. Recently, stabilized
weights were developed to reduce the influence of extreme inverse
probability of treatment-weighted weights in estimating treatment ef-
fects. The objective of this research was to use adjusted Kaplan-Meier
estimates and modified log-rank and Wilcoxon tests to examine the
effect of a treatment that varies over time in an observational study.
Methods: We proposed stabilized weight adjusted Kaplan-Meier esti-
mates and modified log-rank and Wilcoxon tests when the treatment
was time-varying over the follow-up period. We applied these new
methods in examining the effect of an anti-platelet agent, clopidogrel,
on subsequent events, including bleeding, myocardial infarction, and
death after a drug-eluting stent was implanted into a coronary artery.
In this population, clopidogrel use may change over time based on a O
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doi:10.1016/j.jval.2011.07.010atient’s behavior (e.g., nonadherence) and physicians’ recommenda-
ions (e.g., end of duration of therapy). Consequently, clopidogrel use
as treated as a time-varying variable. Results: We demonstrate that
) the sample sizes at three chosen time points are almost identical in
he original and weighted datasets; and 2) the covariates between pa-
ients on and off clopidogrel were well balanced after stabilized
eights were applied to the original samples. Conclusions: The stabi-
ized weight-adjusted Kaplan-Meier estimates and modified log-rank
nd Wilcoxon tests are useful in presenting and comparing survival
unctions for time-varying treatments in observational studies while
djusting for known confounders.
eywords: Kaplan Meier estimates, Observational study, Stabilized
eights, Stents, Time-varying treatment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Kaplan-Meier estimator of survival functions was developed to
account for censoring resulting from incomplete information on
outcomes or their timing [1]. Because Kaplan-Meier methods do
not control for confounding nor accommodate time-varying treat-
ments, other methods such as parametric survival models and
proportional hazards models are often employed [2,3]. Methods
using inverse probability of treatment weight (IPTW) have ex-
panded the analytic tools available to researchers to make unbi-
ased comparisons between treatment groups in observational
studies [4–6]. Cole et al. [7] used IPTW in a marginal structural
left-censored linear model for analyzing the effect of highly active
antiretroviral therapy on semiannual repeated assessments of vi-
ral load. Cook et al. [8] studied aspirin effects on cardiovascular
death in marginal structural discrete-time survival models with
time-dependent inverse probability weights. None of those stud-
ies used Kaplan-Meier estimates. Xie and Liu [9] developed an ad-
usted Kaplan-Meier estimator to reduce confounding effects us-
ng IPTW for observational studies with time-invariant treatment
n which each observation is weighted by its inverse probability of
eing in a certain group. Their article proposes a weighted log-
* Address correspondence to: Stanley Xu, Kaiser Permanente Color
CO 80111 USA.
E-mail: stan.xu@kp.org.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.rank test for comparing survival functions among treatment
groups. Sugihara [10] extended this work by proposing IPTW ad-
justed Kaplan-Meier estimates and a log-rank test that allows
comparisons of treatments in settings where there are more than
two treatment options.
Several studies have used improved IPTW, namely stabilized
weights (SWs), to estimate effects of time-varying treatments in
marginal structure models, which involve a range of statistical
models, including Cox proportional hazards models for survival
data, linear mixed models for repeated measures, and logistic re-
gression models [11–17]. SWs improve on the nonstabilized IPTW
methods by reducing the weights of treated subjects with low pro-
pensity scores anduntreated subjectswithhigh propensity scores.
In a recent study [18] describing analysis methods for observa-
ional studies with time-invariant treatment, we demonstrated
hat the use of the SWs 1) produced appropriate estimation of the
ariance ofmain effect andmaintained an appropriate type I error
ate; and 2) yielded appropriate confidence intervals of relative
isks in Poisson regression analyses. That study, however, did not
xplore the influence of SWs when treatments are time-varying.
Time-varying treatments are common. We were motivated
o further explore the use of SWs by an observational study
Institute for Health Research, 10065 East HarvardAvenue, Denver,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
K
r
l
o
c
t
a
m
m
c
s
t
K
t
f
i
f
e
f
b
l
t
e
t
t
v
S
a
s
t
a
t
p
o
a
w
168 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4where we examined the effects of an anti-platelet medication,
clopidogrel, on subsequent risk of bleeding, myocardial infarc-
tion (MI), and death after a drug-eluting stent (DES) was im-
planted into a coronary artery [19]. In that study patients were
followed after hospital discharge for up to 18 months. Clopi-
dogrel use was not randomly assigned to patients in that study.
Physicians often consider aspects of a patient’s clinical condi-
tion, such as bleeding history and risk factors for MI and death,
when deciding whether or not to initiate clopidogrel therapy
and how long to continue clopidogrel treatment. The mean
number of clopidogrel-covered days was 257  159 days based
on pharmacy dispensing data. Almost half (49.1%) of patients
received clopidogrel for longer than 6 months. Because of the
reasons above, standard Kaplan-Meier method cannot be ap-
plied to assess the risk and benefit of clopidogrel use after DES
implantation in this observational study setting. Although a rel-
ative-risk-like measure such as the hazard ratio is commonly
used to evaluate the effect of treatment, caution about inter-
preting the hazard ratio need to be taken, especially when it is
not consistent over time [20]. Kaplan-Meier estimates and the
aplan-Meier curves are useful and informative because they
eveal the details of changes in survival function over a fol-
ow-up period.
In this research we developed a separate probabilistic model
f being on clopidogrel for every day of follow-up. Then the
orresponding time-dependent SWs were calculated and used
o weight both the number of events and the number of subjects
t risk during every day of follow-up. We then used this infor-
ation to develop SW-adjusted Kaplan-Meier estimates and
odified log-rank and Wilcoxon tests useful for estimating and
omparing survival functions of time-varying treatments in ob-
ervational studies. Adjusting for covariates when treatment is
ime-varying in observational studies using SWs, the resulting
aplan-Meier curves represent survival function estimates for
hose never treated versus those always treated.
Statistical Methods
Kaplan-Meier estimates when treatment is time-invariant
Let zi be an indicator of binary treatment with 1 for treated and 0
or untreated for subject i. Suppose that there are nj subjects at risk
at time j, with n1j subjects who received the treatment and n0j
subjects who did not, njn0jn1j. In group z, there are dzj events of
nterest out of nzj subjects. The Kaplan-Meier estimates of survival
unction for group z at time j is given by Szj  k1j 1  hzk, where
hzjdzj/nzj is the hazard function at time j [1]. The Kaplan-Meier
stimates can be plotted to display the survival function over time
or each group. Two common nonparametric statistical tests have
een widely used for comparing two groups of survival data: the
og-rank test and the Wilcoxon test [21–24].
Crude Kaplan-Meier estimates when treatment is
time-varying
Because the treatment is time-varying, we add subscribe j to the
indicator of binary treatment, zij, with 1 for treated and 0 for un-
treated for subject i at time j. Notations remain the same for the
number of subjects at risk at time j (nzj), the number of events at
ime j (dzj), the hazard function (hzj), and the survival function (Szj)
xcept that subjects may switch their treatment status between
reated and untreated at any time during the follow-up. Let yzij be
he outcome variable with 1 for event and 0 for no event, and let Izij
be an indicator that subject i is at risk in group z at time j. When
treatment is time-varying, we propose to calculate the number of
events and the number of subjects at risk as dc  nzj y I andzj i1 zij zij
nzj
c i1nzj Izij, respectively. For each group, the crude Kaplan-Meierestimates for the hazard function for group z at time j can be
calculated as
hzj
c 
dzj
c
nzj
c
The corresponding survival probability at time j, given survival to
time j-1, is 1  hzj
c . The crude Kaplan-Meier estimates of the sur-
ival function at time j is
zj
c  
k1
j
1hzkc  (1)
SW-adjusted Kaplan-Meier estimates when treatment is
time-varying
We first calculate the time-dependent SW for each subject. Let Xij
be a row vector of covariates for the probability of treatment and
outcome, ij be the propensity score. For those treated, the pro-
pensity score ij is the probability of treatment given the observed
covariates Xij, prob (zij1|Xij). For those not treated, it is 1- prob
(zij1|Xij) [4–6]. The probability of treatment can be estimatedwith
logistic regression model: probzij  1Xij 
expXijj
1expXijj
where j
is a column vector of parameters to be estimated at time j from
data. For the same covariate (fixed or time-varying), estimated
values of parameters may vary over time because the status of
clopidogrel use changes. At time j for subject i, if zij1, then the
tabilized weightWij 
Pj
ij
, and if zij0 thenWij 
1Pj
1ij
where pj is
he probability of treatment at time j without considering covari-
tes [16,17]. Theoretically, and by simulation, it has been shown
hat the use of the SWs in analyzing observational data has appro-
riate type I error rates when the treatment is time-invariant [18].
To adjust for known covariates, we propose to apply SW to
btain the number of events and the number of subjects at risk
s dzj
w i1nzj wzijyzijIzijand nzjw i1nzj wzijIzij , respectively. For each
group, the SW-adjusted Kaplan-Meier estimates of the survival
function for group z at time j can be calculated as
Szj
w 
k1
j
(1hzk
w ) (2)
here hzj
w 
dzj
w
nzj
w
is the corresponding hazard function.
Modified log-rank and Wilcoxon tests for comparing the SW-
adjusted survival data of two groups are detailed in the Appendix
in Supplemental Materials at: doi:10.1016/j.jval.2011.07.010.
Clopidogrel Use Example
We applied the SW-adjusted Kaplan-Meier estimates, the modi-
fied log-rank test and the modified Wilcoxon test to examine the
benefit and risk of clopidogrel use for patients who received a DES.
Three endpoints, bleeding, MI, and death, are considered in this
observational study. The time origin for the survival analysis is
day 1 after hospital discharge following DES surgery. In this exam-
ple, the time-dependent treatment was a dichotomous variable
Table 1 – Sample sizes in the original and weighted data
sets.
Days after hospital
discharge
Original
data set
Weighted
data set
1 6447 6418
180 5422 5422
360 4447 4404
(169V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4with 1 or 0 indicating the use of clopidogrel on that day (i.e., no lag
or cumulative functions were used), implying an acute effect of
clopidogrel on all endpoints. The following steps were taken to
analyze the data. Step 1) fit separate logistic regressionmodels for
every day of the follow-up period. At this step the dichotomous
variable indicating the use of clopidogrel on that day is the depen-
dent variable; Step 2) calculate the stabilizedweights for every day
of follow-up period for each individual as defined in the Statistical
Methods section; Step 3) calculate the crude and SW-adjusted
Kaplan-Meier estimates as in equations (1) and (2); Step 4) obtain
the P values from the modified log-rank test and Wilcoxon test
see Appendix in Supplemental Materials at: doi:10.1016/j.
Table 2 – Comparison of covariates at 1 day after hospital d
Variables Clopidogrel use
Off O
Age group (%)
65 43.0 52
65 – 75 29.0 27
75 28.0 20
Male (%) 66.2 71
BMI 33 (%) 22.9 18
Prior MI (%) 38.0 24
Previous valve surgery (%) 1.29 1
Diabetes (%) 40.3 29
Renal insufficiency (%)
1 renal failure and on dialysis 2.70 1
2 renal failure without dialysis 4.11 3
3 no renal failure 93.19 95
Cerebrovascular disease (%) 14.0 7
Peripheral vascular disease 16.43 9
Chronic lung disease (%) 16.9 13
Hypertension (%) 81.2 75
Tobacco use (%)
1 current use 15.6 18
2 former use 48.1 43
3 never used 36.3 38
Hypercholesterolemia (%) 73.5 81
Previous revascularization (%) 48.0 29
Previous congestive heart failure (%) 80.2 71
Cardiogenic shock (%) 3.4 1
Use of glycoprotein IIb-IIIa inhibitor (%)
0 no use 50.2 35
1 contraindicated 0.6 0
2 yes, used 49.2 64
Left ventricular function (%) 59.6 44
Discharge location (%)
1 66.5 71
2 23.5 17
3 10.0 11
Periprocedural MI (%) 0.94 0
No. of stents (%)
1 37.4 42
2 32.3 29
3 12.9 14
4 17.4 14
Any lesion complication (%) 3.8 4
1 mm  longest stent size  21 mm (%) 87.2 92
Post-procedure TIMI flow (%) 98.2 97
Off label status (%) 74.8 67
Length of stay (meanSD) 2.4 (3.6) 2.1
No. of lesions (meanSD) 1.7 (0.9) 1.7BMI, body mass index; MI, myocardial infarction; TIMI, thrombolysis in mjval.2011.07.010). We also compared the sample sizes between the
original and the weighted data sets. In addition we evaluated the
covariates balance between those on and off clopidogrel at every
day of the follow-up period. We present the details on covariate
balance for three arbitrary time points, 1, 180, and 365 days after
hospital discharge.
SWs
Because a patient could discontinue and then restart clopidogrel
therapyduring the follow-upperiod,wemodeledclopidogreluseasa
time-varying dependent variable in creating SW. We fit separate lo-
arge.
riginal data Clopidogrel use in weighted data
P Off On P
0.0001 0.21
48.1 51.0
29.9 27.3
22.0 21.7
0.002 70.9 70.3 0.73
0.004 20.8 19.3 0.31
0.0001 28.7 26.9 0.29
0.85 0.97 1.23 0.54
0.0001 32.7 30.7 0.26
0.03 1.53 1.99 0.66
3.24 3.34
95.2 94.7
0.0001 9.5 8.5 0.38
0.0001 11.3 10.7 0.65
0.02 13.4 14.4 0.44
0.0001 76.4 76.3 0.91
0.050 0.91
17.5 17.6
45.1 44.3
37.4 38.1
0.0001 79.7 80.4 0.63
0.0001 34.6 32.8 0.30
0.0001 75.2 72.6 0.12
0.0001 2.2 1.6 0.29
0.0001 0.98
38.3 37.9
0.3 0.3
61.4 61.8
0.0001 49.3 46.1 0.08
0.0001 0.24
68.7 71.3
18.7 17.7
12.6 11.0
0.98 1.23 1.04 0.63
0.01 0.46
38.7 41.6
30.3 29.3
15.0 14.1
16.0 15.0
0.34 4.9 4.5 0.62
0.0001 89.9 91.7 0.09
0.43 96.4 97.8 0.006
0.0001 72.7 68.0 0.008
0.02 2.3 (3.2) 2.1 (3.4) 0.16
0.86 1.73 (0.89) 1.66 (0.87) 0.03isch
in o
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.5
.1
.4
.3
.8
.6
.22
.1
.73
.00
.26
.4
.79
.9
.2
.0
.9
.1
.1
.9
.7
.4
.3
.2
.5
.3
.7
.0
.3
.95
.0
.0
.3
.7
.5
.2
.8
.5
(3.2)
(0.9)yocardial infarction.
170 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4gistic regression models for every day of follow-up until loss to fol-
low-upordeath,while adjusting for a set of knowncovariates includ-
ing age, sex, body mass index, prior MI, previous valve surgery,
diabetes, renal insufficiency, cerebrovascular disease, peripheral
vascular disease, chronic lung disease, hypertension, current to-
baccouse, previous revascularization, previous congestiveheart fail-
ure, cardiogenic shock, use of a glycoprotein IIb-IIIa inhibitor upon
hospital admission, left ventricular function assessment, discharge
location, periprocedural MI, number of stents implanted, any lesion
complication, an indicator for the longest stent being between 1mm
and 21 mm, post-procedure thrombolysis in myocardial infarction
flow, off-label stent status, length of stay, number of lesions, and an
Table 3 – Comparison of covariates at 180 days after hospi
Variables Clopidogrel u
Off
Age group (%)
65 45.0
65 –  75 30.4
75 24.6
Male (%) 68.0
BMI 33 (%) 17.3
Prior MI (%) 26.2
Previous valve surgery (%) 1.5
Diabetes (%) 29.9
Renal insufficiency (%)
1 renal failure and on dialysis 2.0
2 renal failure without dialysis 3.9
3 no renal failure 94.1
Cerebrovascular disease (%) 9.2
Peripheral vascular disease 11.6
Chronic lung disease (%) 16.3
Hypertension (%) 75.9
Tobacco use (%)
1 current use 17.8
2 former use 45.0
3 never used 37.2
Hypercholesterolemia (%) 80.7
Previous revascularization (%) 30.8
previous congestive heart failure (%) 53.8
Cardiogenic shock (%) 0.9
Use of glycoprotein IIb-IIIa inhibitor (%)
0 no use 33.1
1 contraindicated 0.5
2 yes, used 66.4
Left ventricular function (%) 37.3
Discharge location (%)
1 70.8
2 18.7
3 10.5
Periprocedural myocardial infarction (%) 0.9
No. of stents (%)
1 48.8
2 28.3
3 12.6
4 10.2
Any lesion complication (%) 4.0
1 mm  longest stent size  21 mm (%) 95.3
Post-procedure TIMI flow (%) 98.4
Off label status (%) 59.4
Length of stay (meanSD) 2.2 (4.4) 2
No. of lesions (meanSD) 1.6 (0.8) 1BMI, body mass index; MI, myocardial infarction; TIMI, thrombolysis in mindicator for prior bleeding. Among these variables, indicators for
prior bleeding and MI were updated for each successive logistic re-
gression model; other variables are measured at baseline. Off-label
stent status is an indicator for off-labeluseofdrug-eluting stents that
occurred when the stent was implanted outside of Food and Drug
Administration-approved clinical scenarios. Additional details on
the variables for this analysis are available at http://www.ncdr.com/
WebNCDR/NCDRDocuments/datadictdefsonlyv30.pdf. There were
6447 patients with no missing data for covariates included in the
analyses. SWswere then calculated according to the formulas in the
Statistical Methods section for each individual on each day of the
follow-up period until either the subject was censored or died.
ischarge.
original data Clopidogrel use in weighted data
P Off On P
0.0001 0.50
49.8 51.5
28.8 27.5
21.4 20.9
0.022 71.2 70.5 0.64
0.01 19.2 19.6 0.77
1.00 25.4 26.6 0.41
0.25 1.2 1.2 0.99
0.97 30.0 30.2 0.90
0.06 0.34
2.1 1.6
3.6 3.0
94.4 95.3
0.081 8.3 8.2 0.97
0.04 10.4 10.2 0.87
0.005 14.9 13.9 0.34
0.90 75.1 75.8 0.60
0.83 0.91
18.1 18.3
43.9 44.3
38.0 37.4
0.43 80.3 80.0 0.83
0.202 31.8 32.5 0.67
0.001 71.0 71.2 0.885
0.04 1.7 1.6 0.65
0.008 0.94
37.1 36.6
0.3 0.3
62.6 63.1
0.0001 44.4 46.3 0.23
0.71 0.81
70.6 70.6
19.0 18.4
10.4 11.0
0.57 0.8 0.7 0.81
0.0001 0.71
41.6 42.3
30.8 29.2
13.2 13.8
14.3 14.7
0.69 4.2 4.2 0.96
0.0001 91.9 91.7 0.78
0.12 98.1 97.8 0.52
0.0001 67.5 67.4 0.94
) 0.45 2.1 (4.3) 2.0 (2.1) 0.43
) 0.0001 1.6 (0.9) 1.6 (0.9) 0.62tal d
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1.7
37.9
0.2
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49.1
70.6
18.2
11.3
0.7
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171V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4Regardless of endpoints, we used the daily SWs to examine the
sample sizes (Table 1) and covariates balance at three arbitrarily cho-
sen time points: day 1, 180, and 360 out of 540 days after hospital
discharge (Tables 2–4). Because SW-adjusted Kaplan-Meier esti-
ates in equation (2) andmodified log-rank andWilcoxon tests (see
ppendix in Supplemental Materials at: doi:10.1016/j.jval.
011.07.010) for an endpoint depend on only the SWs on dayswith the
pecificendpoint event, differentSWsareapplied for eachdistinct end-
oint and are re-estimated each time an endpoint occurs.
Sample sizes in the weighted data sets
Table 1 shows the sample sizes in the original and weighted data
Table 4 – Comparison of covariates at 360 days after hospi
Variables Clopidogrel us
Off
Age group (%) 47.9
65
65 –  75 30.2
75 21.8
Male (%) 69.8
BMI 33 (%) 17.3
Prior MI (%) 24.9
Previous valve surgery (%) 1.0
Diabetes % 27.6
Renal insufficiency (%)
1 renal failure and on dialysis 1.0
2 renal failure without dialysis 3.5
3 no renal failure 95.5
Cerebrovascular disease (%) 7.6
Peripheral vascular disease 9.6
Chronic lung disease (%) 14.5
Hypertension (%) 76.2
Tobacco use (%)
1 current use 18.0
2 former use 45.3
3 never used 36.7
Hypercholesterolemia (%) 82.7
Previous revascularization (%) 29.4
previous congestive heart failure (%) 55.5
Cardiogenic shock (%) 1.1
Use of glycoprotein IIb-IIIa inhibitor (%)
0 no use 34.1
1 contraindicated 0.4
2 yes, used 65.5
Left ventricular function (%) 37.7
Discharge location (%)
1 71.0
2 18.9
3 10.1
Periprocedural myocardial infarction (%) 0.9
No. of stents (%)
1 46.2
2 28.6
3 13.4
4 11.8
Any lesion complication (%) 3.9
1 mm  longest stent size  21 mm (%) 95.2
Post-procedure TIMI flow (%) 98.3
Off label status (%) 61.3
Length of stay (meanSD) 2.0 (3.5) 2.
No. of lesions (meanSD) 1.6 (0.9) 1.
BMI, body mass index; MI, myocardial infarction; TIMI, thyrombolysisets at day 1, 180, and 360 out of 540 days after hospital discharge.These results demonstrate that the use of stabilized weights pre-
serves the original sample size and thus the use of SWs would not
be expected to inflate type I error rates in relevant statistical hy-
pothesis tests including the modified log-rank andWilcoxon tests
for comparing survival data of two groups.
Covariate balance between those on and off clopidogrel use
SWweightings improved covariate balance in analyzing the clopi-
dogrel use data. During the 540 days of follow-up, in the original
cohort the mean number of unbalanced covariates (statistically
significant based on P  0.05) was 13.5 with a minimum of eight
and amaximum of 20 unbalanced covariates out of 27, whereas in
ischarge.
original data Clopidogrel use in weighted data
P Off On P
0.0001 50.6 52.3 0.37
28.9 27.0
20.5 20.7
0.42 70.3 71.7 0.32
0.0001 19.0 20.3 0.27
0.51 25.5 26.8 0.3
0.94 1.1 1.1 0.86
0.01 28.6 30.9 0.08
0.003 0.30
1.3 1.9
3.1 3.2
95.5 94.9
0.56 8.0 8.2 0.72
0.62 9.5 9.9 0.63
0.02 14.1 12.3 0.2
0.55 75.7 75.3 0.73
0.02 0.51
17.7 19.0
43.4 42.6
38.9 38.4
0.0001 81.2 79.6 0.17
0.006 31.0 32.4 0.32
0.0001 66.6 70.6 0.003
0.02 1.4 1.6 0.67
0.03 0.68
36.7 35.5
0.3 0.3
63.0 64.3
0.0001 45.1 47.1 0.20
0.001 0.49
70.0 68.3
19.0 20.2
11.0 11.5
0.31 0.9 0.7 0.62
0.0001 0.32
42.9 41.4
29.7 28.6
13.4 14.4
14.1 15.6
0.18 4.1 4.5 0.43
0.0001 93.2 92.1 0.14
0.01 97.9 97.7 0.57
0.0001 65.4 67.6 0.14
0.22 2.1 (4.1) 2.1 (2.1) 0.97
0.20 1.7 (0.9) 1.7 (0.9) 0.17
yocardial infarction.tal d
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2.3
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2.0
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0.6
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172 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4ates was 1.2 with a minimum of zero and a maximum of five
unbalanced covariates out of 27. A mean of 1.2 (out of 27) unbal-
anced covariates is consistent with chance, based on a 0.05 type I
error rate. For example, with SWs applied at day 1 after hospital
discharge, 21 unbalanced covariates in the original cohort became
balanced; among the remaining six covariates, three balanced co-
variates in the original cohort remained balanced, two balanced
covariates in the original cohort became unbalanced, and one un-
balanced covariate in the original cohort remained unbalanced
(Table 2). With SWs applied at day 180 after hospital discharge, 13
unbalanced covariates in the original cohort became balanced, the
remaining 14 balanced covariates in the original cohort remained
balanced (Table 3). With SWs applied at day 360 after hospital
discharge, 16 unbalanced covariates in the original cohort became
balanced; among the remaining 11 covariates, 10 balanced covari-
ates in the original cohort remained balanced, one unbalanced
covariates in the original cohort remained unbalanced (Table 4).
Kaplan-Meier estimates of survival functions
Crude and SW-adjusted Kaplan-Meier estimates of survival func-
tions for bleeding, MI, and death are displayed in Figures 1 and 2.
The corresponding P values based on the crude and modified log-
rank and Wilcoxon tests are shown in Table 5. Although both the
crude and SW-adjusted methods showed that clopidogrel use sig-
nificantly increased the risk of bleeding and decreased the risk of
death during the 540 days of follow-up after hospital discharge,
the latter method provided smaller P values. Results using the
crude log-rank and Wilcoxon tests suggested there was no statis-
tically significant reduction in MI incidence associated with clopi-
dogrel use. The SW-adjusted log-rank and Wilcoxon tests, how-
ever, showed a statistically significant reduction of MI incidence
associated with clopidogrel use.
We also fit Cox regression models with time-dependent clopi-
dogrel treatment [25] adjusting for the same covariates used in
creating SWs. Clopidogrel use significantly increased the risk of
Fig. 1 – Crude Kaplan-Meier curves for blebleeding (hazard ratio 1.52; P  0.010) and decreased mortality f(hazard ratio 0.67; P 0.018). Although not statistically significant,
it also decreased the risk of MI (hazard ratio 0.78; P  0.080).
Discussion
This research extends prior work on IPTW adjusted Kaplan-Meier
estimates [9] to include time-varying treatments. Equations for
modified log-rank and Wilcoxon tests of survival functions were
also detailed and explored using a specific study example. Our
study demonstrated that the sample sizes at three time points
were almost identical in the original and weighted datasets, sug-
gesting that the use of SWs would not be expected to inflate type I
error rates. The balance in the covariates between patients on and
off clopidogrel was largely achieved after SWs were applied to the
original sample. At each event time j, for the entire population of
patients who survived to time j-1, the survival probabilities for
treated and not treated are calculated after covariates are bal-
anced by applying SWs. Because re-estimating probabilities of
treatment removes differences between persons on and off treat-
ment and prior history of treatment does not influence the calcu-
lation, the switch between on and off clopidogrel at time j from
time j-1 would not change the interpretation of the survival prob-
bilities for the two groups at time j when compared to those from
urvival analysis with time-invariant treatment. The resulting cu-
ulative survival probabilities as displayed in Kaplan-Meier
urves represent the estimates for groups that are always treated
r never treated. Thus, we believe that SW-adjusted Kaplan-Meier
stimates and themodified log-rank andWilcoxon tests presented
ere are proper for examining the risk and benefit of clopidogrel
se after DES implantationwith time-varying treatment adjusting
or covariates.
In creating SWs, logistic regression models were fit for every
ay of the follow-up period so that the covariate balance could be
valuated and all three outcomes of clopidogrel use data could be
nalyzedwith the samedata steps. Fitting logistic regressionmod-
ls for every day of follow-up periods could be too time-consuming
g, myocardial infarction (MI), and death.edinor studies that have a long follow-up period. SW-adjusted
a173V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4Kaplan-Meier estimates in equation (2) andmodified log-rank and
Wilcoxon tests (Appendix in Supplemental Materials at: doi:
10.1016/j.jval.2011.07.010) do not depend on the SWs on dayswith-
out events. In the otherwords, only the SWs on event days need be
calculated, thus reducing the number of logistic regressionmodels
necessary to create SWs.
The log-rank test and theWilcoxon test of survival functions can
produce disparate estimates of significance because the two tests
weight time periods of follow-up differently [3]. The log-rank test
weights the entire follow-up period equally, whereas the Wilcoxon
test weights by the sample size at each time point and therefore
weights earlier timesmore heavily. In the example described in this
article, small differences in significance levelswerenoted for the two
tests although the conclusions remainedconsistent.Whendisparate
results do occur, the differences can provide researchers with in-
sights as to where the survival functions differ [3].
Although the clinical conclusions from the Cox regression
models adjusting for the same covariates with time-dependent
clopidogrel treatment remain the same as from SW-adjusted
Kaplan-Meier approach, the P values may not be the same. For
example, for the MI outcome, the Cox model yielded a marginally
significant P value of 0.08 whereas the SW-adjusted log-rank test
nd Wilcoxon test produced P values less than 0.0001. In the Cox
model, covariates are included as predictors of the outcome along
with the indicator for clopidogrel use, whereas in the SW-adjusted
Kaplan-Meier approach the covariates are treated as confounders
Fig. 2 – Stabilized weight adjusted Kaplan-Meier cu
Table 5 – P values for bleeding, myocardial infarction
(MI), and death based on crude and stabilized weights
(SW) adjusted log-rank and Wilcoxon tests.
Bleeding MI Death
Crude SW Crude SW Crude SW
Log-rank 0.0056 0.0002 0.136 0.0001 0.0079 0.0020
Wilcoxon 0.0150 0.0003 0.052 0.0001 0.0106 0.0033that are associated with both the outcome and the clopidogrel use
status. Also the Cox model requires a proportional hazard as-
sumption [3], but the SW-adjusted Kaplan-Meier approach does
not. In the presence of strong confounding or violation of the pro-
portional hazard assumption, results from the Coxmodelmay not
be valid. For example, the Kaplan-Meier curves for MI in Figure 1
clearly suggest nonproportional hazards between the two groups,
with the Off Clopidogrel group dropping rapidly within the first 50
days, and paralleling the On Clopidogrel group thereafter.
Examination of covariate balance in this studywas limited.We
provide a summary of covariate balance over the entire follow-up
period, and show covariate differences at three arbitrary time
points using p-values to demarcate potential imbalance. P values
are affected by sample size, do not adequately focus on actual
difference magnitudes, and have other well-documented short-
comings [26]. Time-varying covariates can result in the need for
large number logistic regression iterations, as in the example
study where 540 treatment models were fit. Examination of the
actual magnitude of difference across all covariates for each indi-
vidual logistic regression alone in such instances is impractical.
For the three time periods shown here, some of the covariate bal-
ance differenceswere likely related to changes in the proportion of
persons treated with clopidogrel on that day. At day 1 after hospi-
tal discharge, only 15% of patients were not on clopidogrel,
whereas 25% and 52% were not on clopidogrel at 180 days and 360
days after hospital discharge, respectively. Clearly, assessing and
confirming adequate covariate balance in IPTW time-varying
models is challenging and needs further study. An additional lim-
itation of this research is the single study application. Further
work with simulations and contrasts to other methods and other
study applications would help elucidate the advantages and dis-
advantages of this approach.
Conclusions
This article examined the use of SWs in Kaplan-Meier estimates
for bleeding, myocardial infarction (MI), and death.rveswith time-varying treatments in observational studies. Related
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174 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 6 7 – 1 7 4methods include marginal structural logistic models that, for ex-
ample, have been used to explore the effect of iron supplementa-
tion on anemia in pregnancy [27] and marginal structural Cox
odels that have investigated aspirin effects on cardiovascular
eath [8]. The Kaplan-Meiermethod explored here expands on the
vailable analytic tools and has the advantage of aligning more
irectly to the adjusted survival graphing methods detailed by
ole and Hernán [28]. Analyses of observational studies will con-
inue to be improved by further detailed exploration of these re-
ated methods and further exploration of their use.
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